





CLIENT'S NAME AND ADDRESS : ACROFEMI HEALTHCARE LTD (MEDIWHEEL) F-703, LADO SARAI, MEHRAULI SOUTH WEST DELHI NEW DELHI 110030 DELHI INDIA 8800465156

SRL Ltd Shop CG 017, PALM SPRINGS PLAZA GURUGRAM, 122001 HARYANA, INDIA Tel : 9111591115

PATIENT NAME : ANSHU SHARM	A	PATIENT ID : ANSHF210789282
ACCESSION NO : 0282WC000460	AGE : 33 Years SEX : Female	ABHA NO :
DRAWN :	RECEIVED : 11/03/2023 08:51	REPORTED : 14/03/2023 14:36
REFERRING DOCTOR: SELF CLIENT PATIENT ID :		

MEDI WHEEL FULL BODY HEALTH CHECKUP BELOW 40FEMALE

BLOOD COUNTS, EDTA WHOLE BLOOD				
HEMOGLOBIN (HB)	12.1		12.0 - 15.0	g/dL
METHOD : SPECTROPHOTOMETRY				
RED BLOOD CELL (RBC) COUNT METHOD : IMPEDANCE	5.04	High	3.8 - 4.8	mil/µL
WHITE BLOOD CELL (WBC) COUNT	4.66		4.0 - 10.0	thou/µL
METHOD : IMPEDANCE				
PLATELET COUNT	236		150 - 410	thou/µL
METHOD : IMPEDANCE				
RBC AND PLATELET INDICES				
HEMATOCRIT (PCV)	36.2		36 - 46	%
METHOD : CALCULATED				
MEAN CORPUSCULAR VOLUME (MCV) METHOD : DERIVED FROM IMPEDANCE MEASURE	72.0	Low	83 - 101	fL
MEAN CORPUSCULAR HEMOGLOBIN (MCH)	24.0	Low	27.0 - 32.0	pg
METHOD : CALCULATED PARAMETER			2,10 52.0	P9
MEAN CORPUSCULAR HEMOGLOBIN CONCENTRATION (MCHC) METHOD : CALCULATED PARAMETER	33.3		31.5 - 34.5	g/dL
RED CELL DISTRIBUTION WIDTH (RDW)	14.4	High	11.6 - 14.0	%
METHOD : DERIVED FROM IMPEDANCE MEASURE				
MENTZER INDEX	14.3			
MEAN PLATELET VOLUME (MPV)	10.2		6.8 - 10.9	fL
METHOD : DERIVED FROM IMPEDANCE MEASURE				
WBC DIFFERENTIAL COUNT				
NEUTROPHILS	54		40 - 80	%
METHOD : DHSS FLOWCYTOMETRY				
LYMPHOCYTES	38		20 - 40	%
METHOD : DHSS FLOWCYTOMETRY				
MONOCYTES	6		2 - 10	%
METHOD : DHSS FLOWCYTOMETRY				
EOSINOPHILS	2		1 - 6	%
METHOD : DHSS FLOWCYTOMETRY				
BASOPHILS	0		0 - 2	%
METHOD : IMPEDANCE				
ABSOLUTE NEUTROPHIL COUNT	2.51		2.0 - 7.0	thou/µL











CLIENT'S NAME AND ADDRESS : ACROFEMI HEALTHCARE LTD (MEDIWHEEL) F-703, LADO SARAI, MEHRAULI SOUTH WEST DELHI NEW DELHI 110030 DELHI INDIA 8800465156

SRL Ltd
Shop CG 017, PALM SPRINGS PLAZA
GURUGRAM, 122001
HARYANA, INDIA
Tel : 9111591115

PATIENT NAME : ANSHU SHARMA			PATIENT ID : ANSI	HF210789282
ACCESSION NO : 0282WC000460 AGE :	33 Years SEX : Female		ABHA NO :	
DRAWN : REC	EIVED : 11/03/2023 08:51		REPORTED : 14/03/2023 14:	36
REFERRING DOCTOR : SELF			CLIENT PATIENT ID:	
Test Report Status <u>Final</u>	Results		Biological Reference Interv	al Units
METHOD : DHSS FLOWCYTOMETRY, CALCULATED				
ABSOLUTE LYMPHOCYTE COUNT	1.79		1 - 3	thou/µL
METHOD : DHSS FLOWCYTOMETRY, CALCULATED	1.75		1 5	
ABSOLUTE MONOCYTE COUNT	0.26		0.20 - 1.00	thou/µL
METHOD : DHSS FLOWCYTOMETRY, CALCULATED	0.20		0120 1100	
ABSOLUTE EOSINOPHIL COUNT	0.08		0.02 - 0.50	thou/µL
METHOD : DHSS FLOWCYTOMETRY, CALCULATED	0.00		0.02 0.00	
ABSOLUTE BASOPHIL COUNT	0.01	Low	0.02 - 0.10	thou/µL
METHOD : DHSS FLOWCYTOMETRY, CALCULATED				0.00, μ=
NEUTROPHIL LYMPHOCYTE RATIO (NLR)	1.4			
METHOD : CALCULATED				
ERYTHROCYTE SEDIMENTATION RATE ((ESR),WHOLE			
BLOOD				
E.S.R	9		0 - 20	mm at 1 hr
METHOD : AUTOMATED (PHOTOMETRICAL CAPILLARY ST	OPPED FLOW KINETIC ANALYSIS)			
GLUCOSE FASTING, FLUORIDE PLASMA				
FBS (FASTING BLOOD SUGAR)	83		Normal 75 - 99 Pre-diabetics: 100 - 125 Diabetic: > or = 126	mg/dL
METHOD : SPECTROPHOTOMETRY HEXOKINASE				
GLYCOSYLATED HEMOGLOBIN(HBA1C), BLOOD	EDTA WHOLE			
HBA1C	5.1		Non-diabetic: < 5.7 Pre-diabetics: 5.7 - 6.4 Diabetics: > or = 6.5 ADA Target: 7.0 Action suggested: > 8.0	%
METHOD : CAPILLARY ELECTROPHORESIS				
ESTIMATED AVERAGE GLUCOSE(EAG)	99.7		< 116	mg/dL
METHOD : CALCULATED PARAMETER				
GLUCOSE, POST-PRANDIAL, PLASMA				
PPBS(POST PRANDIAL BLOOD SUGAR)	78		70 - 139	mg/dL
METHOD : SPECTROPHOTOMETRY, HEXOKINASE				
LIPID PROFILE, SERUM				
CHOLESTEROL, TOTAL	158		Desirable cholesterol level < 200 Borderline high cholesterol 200 - 239 High cholesterol > / = 240	mg/dL

METHOD : ENZYMATIC COLORIMETRIC ASSAY











ſ

CLIENT'S NAME AND ADDRESS : ACROFEMI HEALTHCARE LTD (MEDIWHEEL) F-703, LADO SARAI, MEHRAULI SOUTH WEST DELHI NEW DELHI 110030 DELHI INDIA 8800465156

SRL Ltd
Shop CG 017, PALM SPRINGS PLAZA
GURUGRAM, 122001
HARYANA, INDIA
Tel : 9111591115

PATIENT NAME	: ANSHU SHARMA	A	PATIENT ID : ANSHF210789282
ACCESSION NO :	0282WC000460	AGE : 33 Years SEX : Female	ABHA NO :
DRAWN :		RECEIVED : 11/03/2023 08:51	REPORTED : 14/03/2023 14:36
REFERRING DOCT	OR: SELF		CLIENT PATIENT ID:

Test Report Status <u>Final</u>	Results	Results		Biological Reference Interval Units		
TRIGLYCERIDES	98		Normal: < 150 Borderline high: 150 - 199 High: 200 - 499 Very High: >/= 500	mg/dL		
METHOD : ENZYMATIC COLORIMETRIC ASSA	(
HDL CHOLESTEROL	38	Low	Low HDL Cholesterol <40	mg/dL		
METHOD : HOMOGENEOUS ENZYMATIC COLC	DRIMETRIC ASSAY		High HDL Cholesterol >/= 60)		
CHOLESTEROL LDL	99		Adult levels: Optimal < 100 Near optimal/above optimal: 1 129 Borderline high : 130-159 High : 160-189 Very high : = 190	mg/dL 100-		
METHOD : HOMOGENEOUS ENZYMATIC COLO	PRIMETRIC ASSAY		very high . – 190			
NON HDL CHOLESTEROL	120		Desirable : < 130 Above Desirable : 130 -159 Borderline High : 160 - 189 High : 190 - 219 Very high : > / = 220	mg/dL		
METHOD : CALCULATED PARAMETER						
VERY LOW DENSITY LIPOPROTEIN METHOD : CALCULATED PARAMETER	19.6		< OR = 30.0	mg/dL		
CHOL/HDL RATIO	4.2		Low Risk : 3.3 - 4.4 Average Risk : 4.5 - 7.0 Moderate Risk : 7.1 - 11.0 High Risk : > 11.0			
METHOD : CALCULATED PARAMETER			2			
LDL/HDL RATIO	2.6		0.5 - 3.0 Desirable/Low Risk 3.1 - 6.0 Borderline/Moderate >6.0 High Risk	Risk		
METHOD : CALCULATED PARAMETER						









CLIENT'S NAME AND ADDRESS : ACROFEMI HEALTHCARE LTD (MEDIWHEEL) F-703, LADO SARAI, MEHRAULI SOUTH WEST DELHI NEW DELHI 110030 DELHI INDIA 8800465156

SRL Ltd
Shop CG 017, PALM SPRINGS PLAZA
GURUGRAM, 122001
HARYANA, INDIA
Tel : 9111591115

Test Report Status	Final	Results	Biological Reference Interval Units
REFERRING DOCTOR	: SELF		CLIENT PATIENT ID:
DRAWN :		RECEIVED : 11/03/2023 08:51	REPORTED : 14/03/2023 14:36
ACCESSION NO : 02	282WC000460	AGE : 33 Years SEX : Female	ABHA NO :
PATIENT NAME : A	ANSHU SHARMA		PATIENT ID : ANSHF210789282

Interpretation(s)

1) Cholesterol levels help assess the patient risk status and to follow the progress of patient under treatment to lower serum cholesterol concentrations.

2) Serum Triglyceride (TG) are a type of fat and a major source of energy for the body. Both quantity and composition of the diet impact on plasma triglyceride concentrations. Elevations in TG levels are the result of overproduction and impaired clearance. High TG are associated with increased risk for CAD (Coronary artery disease) in patients with other risk factors, such as low HDL-C, some patient groups with elevated apolipoprotein B concentrations, and patients with forms of LDL that may be particularly atherogenic.

3)HDL-C plays a crucial role in the initial step of reverse cholesterol transport, this considered to be the primary atheroprotective function of HDL

4) LDL -C plays a key role in causing and influencing the progression of atherosclerosis and, in particular, coronary sclerosis. The majority of cholesterol stored in atherosclerotic plaques originates from LDL, thus LDL-C value is the most powerful clinical predictor.

5)Non HDL cholesterol: Non-HDL-C measures the cholesterol content of all atherogenic lipoproteins, including LDL hence it is a better marker of risk in both primary and secondary prevention studies. Non-HDL-C also covers, to some extent, the excess ASCVD risk imparted by the sdLDL, which is significantly more atherogenic than the normal large buoyant particles, an elevated non-HDL-C indirectly suggests greater proportion of the small, dense variety of LDL particles

Serum lipid profile is measured for cardiovascular risk prediction.Lipid Association of India recommends LDL-C as primary target and Non HDL-C as co-primary treatment target.

Risk Stratification for ASCVD (Atherosclerotic cardiovascular disease) by Lipid Association of India

Risk Category			
Extreme risk group	A.CAD with > 1 feature of high risk group		
	B. CAD with > 1 feature of Very high risk	group or recurrent ACS (within 1 year) despite LDL-C	
	< or $=$ 50 mg/dl or polyvascular disease		
Very High Risk	1. Established ASCVD 2. Diabetes with 2	major risk factors or evidence of end organ damage 3.	
	Familial Homozygous Hypercholesterolemi	ia	
High Risk	1. Three major ASCVD risk factors. 2. Diabetes with 1 major risk factor or no evidence of end		
	organ damage. 3. CKD stage 3B or 4. 4. LDL >190 mg/dl 5. Extreme of a single risk factor. 6.		
	Coronary Artery Calcium - CAC >300 AU. 7. Lipoprotein a >/= 50mg/dl 8. Non stenotic carotid		
	plaque		
Moderate Risk	2 major ASCVD risk factors		
Low Risk	0-1 major ASCVD risk factors		
Major ASCVD (Atherosclerotic cardiovascular disease) Risk Factors			
1. Age $>$ or $=$ 45 year	1. Age $>$ or $= 45$ years in males and $>$ or $= 55$ years in females 3. Current Cigarette smoking or tobacco use		
2. Family history of premature ASCVD 4. High blood pressure			
5. Low HDL			

Newer treatment goals and statin initiation thresholds based on the risk categories proposed by LAI in 2020.

Risk Group	Treatment Goals		Consider Drug Therapy	
	LDL-C (mg/dl)	Non-HDL (mg/dl)	LDL-C (mg/dl)	Non-HDL (mg/dl)
Extreme Risk Group	<50 (Optional goal	< 80 (Optional goal	>OR = 50	>OR = 80
Category A	< OR = 30)	< OR = 60)		







Patient Ref. No. 775000002565718



CLIENT CODE : C000138354

CLIENT'S NAME AND ADDRESS : ACROFEMI HEALTHCARE LTD (MEDIWHEEL) F-703, LADO SARAI, MEHRAULI SOUTH WEST DELHI NEW DELHI 110030 DELHI INDIA 8800465156

SRL Ltd
Shop CG 017, PALM SPRINGS PLAZA
GURUGRAM, 122001
HARYANA, INDIA
Tel : 9111591115

PATIENT NAME : ANSHU SHARM	A	PATIENT ID : ANSHF210789282
ACCESSION NO : 0282WC000460	AGE : 33 Years SEX : Female	ABHA NO :
DRAWN :	RECEIVED : 11/03/2023 08:51	REPORTED : 14/03/2023 14:36
REFERRING DOCTOR : SELF		CLIENT PATIENT ID :

Test Report Status	<u>Final</u>	Results	Biological Reference Interval Units

Extreme Risk Group	<or 30<="" =="" th=""><th>$\langle OR = 60$</th><th>> 30</th><th>>60</th></or>	$\langle OR = 60$	> 30	>60
Category B				
Very High Risk	<50	<80	>OR= 50	>OR= 80
High Risk	<70	<100	>OR= 70	>OR=100
Moderate Risk	<100	<130	>OR=100	>OR=130
Low Risk	<100	<130	>OR=130*	>OR=160

*After an adequate non-pharmacological intervention for at least 3 months.

References: Management of Dyslipidaemia for the Prevention of Stroke: Clinical Practice Recommendations from the Lipid Association of India. Current Vascular Pharmacology, 2022, 20, 134-155.

LIVER FUNCTION PROFILE, SERUM

,,			
BILIRUBIN, TOTAL	0.3	Upto 1.2	mg/dL
METHOD : COLORIMETRIC DIAZO METHOD			
BILIRUBIN, DIRECT	0.1	< 0.30	mg/dL
METHOD : COLORIMETRIC DIAZO METHOD			
BILIRUBIN, INDIRECT	0.20	0.1 - 1.0	mg/dL
METHOD : CALCULATED PARAMETER			
TOTAL PROTEIN	7.4	6.0 - 8.0	g/dL
METHOD : SPECTROPHOTOMETRY, BIURET			
ALBUMIN	4.6	3.97 - 4.94	g/dL
METHOD : SPECTROPHOTOMETRY, BROMOCRESOL GREEN(BC	G) - DYE BINDING		
GLOBULIN	2.8	2.0 - 3.5	g/dL
METHOD : CALCULATED PARAMETER			
ALBUMIN/GLOBULIN RATIO	1.6	1.0 - 2.1	RATIO
METHOD : CALCULATED PARAMETER			
ASPARTATE AMINOTRANSFERASE (AST/SGOT)	17	< OR = 35	U/L
METHOD : SPECTROPHOTOMETRY, WITH PYRIDOXAL PHOSPHA	ATE ACTIVATION-IFCC		
ALANINE AMINOTRANSFERASE (ALT/SGPT)	27	< OR = 35	U/L
METHOD : SPECTROPHOTOMETRY, WITH PYRIDOXAL PHOSPHA	ATE ACTIVATION-IFCC		
ALKALINE PHOSPHATASE	84	35 - 104	U/L
METHOD : SPECTROPHOTOMETRY, PNPP, AMP BUFFER - IFCC			
GAMMA GLUTAMYL TRANSFERASE (GGT)	19	0 - 40	U/L
METHOD : ENZYMATIC COLORIMETRIC ASSAY STANDARDIZED) AGAINST IFCC / SZASZ		
LACTATE DEHYDROGENASE	138	125 - 220	U/L
METHOD : SPECTROPHOTOMETRY, LACTATE TO PYRUVATE - U	/-IFCC		
BLOOD UREA NITROGEN (BUN), SERUM			
BLOOD UREA NITROGEN	8.0	6 - 20	mg/dL
METHOD : SPECTROPHOTOMETRY, KINETIC TEST WITH UREAS	e and glutamate dehydrogen/	ASE	

CREATININE, SERUM









CLIENT'S NAME AND ADDRESS : ACROFEMI HEALTHCARE LTD (MEDIWHEEL) F-703, LADO SARAI, MEHRAULI SOUTH WEST DELHI NEW DELHI 110030 DELHI INDIA 9800465156 8800465156

SRL Ltd Shop CG 017, PALM SPRINGS PLAZA GURUGRAM, 122001 HARYANA, INDIA Tel: 9111591115

PATIENT NAME	: ANSHU SHARM	A.		PATIENT ID	ANSHF210789282
ACCESSION NO :	0282WC000460	AGE: 33 Years	SEX : Female	ABHA NO :	
DRAWN :		RECEIVED : 11/03	3/2023 08:51	REPORTED : 14/03/	2023 14:36
REFERRING DOCT	OR: SELF	CLIENT PATIENT ID :		ID :	

REFERRING DOCTOR : SELF

Test Report Status	<u>Final</u>	Results	Biological Reference Interval Units	
CREATININE		0.60	0.5 - 0.9	mg/dL
METHOD : SPECTROPHOTON	IETRIC, JAFFE'S KINETICS			
BUN/CREAT RATIO				
BUN/CREAT RATIO		13.33	8.0 - 15.0	
METHOD : CALCULATED PAR	RAMETER			
URIC ACID, SERUM				
URIC ACID		5.2	2.4 - 5.7	mg/dL
METHOD : SPECTROPHOTON	1ETRY, URICASE			
TOTAL PROTEIN, SE	RUM			
TOTAL PROTEIN		7.4	6.0 - 8.0	g/dL
METHOD : SPECTROPHOTON	1ETRY, BIURET			
ALBUMIN, SERUM				
ALBUMIN		4.6	3.97 - 4.94	g/dL
METHOD : SPECTROPHOTON	1ETRY, BROMOCRESOL GRE	EN(BCG) - DYE BINDING		
GLOBULIN				
GLOBULIN		2.8	2.0 - 3.5	g/dL
METHOD : CALCULATED PAR	RAMETER			
ELECTROLYTES (NA)	/K/CL), SERUM			
SODIUM, SERUM		136	136 - 145	mmol/L
METHOD : ISE INDIRECT				
POTASSIUM, SERUM		4.4	3.5 - 5.1	mmol/L
METHOD : ISE INDIRECT				
CHLORIDE, SERUM		101	98 - 107	mmol/L
METHOD : ISE INDIRECT				











CLIENT'S NAME AND ADDRESS : ACROFEMI HEALTHCARE LTD (MEDIWHEEL) F-703, LADO SARAI, MEHRAULI SOUTH WEST DELHI NEW DELHI 110030 DELHI INDIA 8800465156

<u>Final</u>

SRL Ltd
Shop CG 017, PALM SPRINGS PLAZA
GURUGRAM, 122001
HARYANA, INDIA
Tel : 9111591115

Biological Reference Interval Units

PATIENT NAME : ANSHU SHARMA	A	PATIENT ID : ANSHF210789282
ACCESSION NO : 0282WC000460	AGE : 33 Years SEX : Female	ABHA NO :
DRAWN :	RECEIVED : 11/03/2023 08:51	REPORTED : 14/03/2023 14:36
REFERRING DOCTOR : SELF		CLIENT PATIENT ID :
() () () () () () () () () ()		

Results

Interpretation(s)

Test Report Status

Sodium	Potassium	Chloride
Decreased in:CCF, cirrhosis, vomiting, diarrhea, excessive sweating, salt-losing nephropathy, adrenal insufficiency, nephrotic syndrome, water intoxication, SIADH. Drugs: thiazides, diuretics, ACE inhibitors, chlorpropamide, carbamazepine, anti depressants (SSRI), antipsychotics.	Decreased in: Low potassium intake,prolonged vomiting or diarrhea, RTA types I and II, hyperaldosteronism, Cushing's syndrome,osmotic diuresis (e.g., hyperglycemia),alkalosis, familial periodic paralysis,trauma (transient).Drugs: Adrenergic agents, diuretics.	Decreased in: Vomiting, diarrhea, renal failure combined with salt deprivation, over-treatment with diuretics, chronic respiratory acidosis diabetic ketoacidosis, excessive sweating, SIADH, salt-losing nephropathy, porphyria, expansion of extracellular fluid volume, adrenalinsufficiency, hyperaldosteronism,metabolic alkalosis. Drugs: chronic laxative,corticosteroids, diuretics.
Increased in: Dehydration (excessivesweating, severe vomiting or diarrhea),diabetes mellitus, diabetesinsipidus, hyperaldosteronism, inadequate water intake. Drugs: steroids, licorice,oral contraceptives.	Increased in: Massive hemolysis, severe tissue damage, rhabdomyolysis, acidosis, dehydration,renal failure, Addison's disease, RTA type IV, hyperkalemic familial periodic paralysis. Drugs: potassium salts, potassium- sparing diuretics,NSAIDs, beta-blockers, ACE inhibitors, high- dose trimethoprim-sulfamethoxazole.	Increased in: Renal failure, nephrotic syndrome, RTA, dehydration, overtreatment with saline, hyperparathyroidism, diabetes insipidus, metabolic acidosis from diarrhea (Loss of HCO3-), respiratory alkalosis, hyperadrenocorticism. Drugs: acetazolamide, androgens, hydrochlorothiazide, salicylates.
Interferences: Severe lipemia or hyperproteinemi, if sodium analysis involves a dilution step can cause spurious results. The serum sodium falls about 1.6 mEq/L for each 100 mg/dL increase in blood glucose.	Interferences: Hemolysis of sample, delayed separation of serum, prolonged fist clenching during blood drawing, and prolonged tourniquet placement. Very high WBC/PLT counts may cause spurious. Plasma potassium levels are normal.	Interferences:Test is helpful in assessing normal and increased anion gap metabolic acidosis and in distinguishing hypercalcemia due to hyperparathyroidism (high serum chloride) from that due to malignancy (Normal serum chloride)

PHYSICAL EXAMINATION, URINE

COLOR

APPEARANCE

PALE YELLOW SLIGHTLY HAZY

Comments

NOTE :MICROSCOPIC EXAMINATION OF URINE IS PERFORMED ON CENTRIFUGED URINARY SEDIMENT. IN NORMAL URINE SAMPLES CAST AND CRYSTALS ARE NOT DETECTED. CHEMICAL EXAMINATION, URINE

PH	6.0	4.7 - 7.5
SPECIFIC GRAVITY	<=1.005	1.003 - 1.035
PROTEIN	NOT DETECTED	NOT DETECTED
GLUCOSE	NOT DETECTED	NOT DETECTED
KETONES	NOT DETECTED	NOT DETECTED
BLOOD	DETECTED (++)	NOT DETECTED
BILIRUBIN	NOT DETECTED	NOT DETECTED
UROBILINOGEN	NORMAL	NORMAL











CLIENT'S NAME AND ADDRESS : ACROFEMI HEALTHCARE LTD (MEDIWHEEL) F-703, LADO SARAI, MEHRAULI SOUTH WEST DELHI NEW DELHI 110030 DELHI INDIA 9800465156 8800465156

SRL Ltd
Shop CG 017, PALM SPRINGS PLAZA
GURUGRAM, 122001
HARYANA, INDIA
Tel : 9111591115

PATIENT NAME : ANSHU SHARMA	PATIENT ID : ANSHF210789282	
ACCESSION NO : 0282WC000460	AGE : 33 Years SEX : Female	ABHA NO :
DRAWN :	RECEIVED : 11/03/2023 08:51	REPORTED : 14/03/2023 14:36
REFERRING DOCTOR : SELF		CLIENT PATIENT ID :
Test Report Status <u>Final</u>	Results	Biological Reference Interval Units
NITRITE	NOT DETECTED	NOT DETECTED
LEUKOCYTE ESTERASE	DETECTED (FEW)	NOT DETECTED
MICROSCOPIC EXAMINATION, UF	RINE	
RED BLOOD CELLS	10 - 15	NOT DETECTED /HPF
PUS CELL (WBC'S)	2-3	0-5 /HPF
EPITHELIAL CELLS	5-7	0-5 /HPF
CASTS	NOT DETECTED	
CRYSTALS	NOT DETECTED	
BACTERIA	NOT DETECTED	NOT DETECTED

METHOD : DIP STICK/MICRO SCOPY/REFLECTANCE SPECTROPHOTOMETRY











CLIENT'S NAME AND ADDRESS : ACROFEMI HEALTHCARE LTD (MEDIWHEEL) F-703, LADO SARAI, MEHRAULI SOUTH WEST DELHI NEW DELHI 110030 DELHI INDIA 8800465156

SRL Ltd
Shop CG 017, PALM SPRINGS PLAZA
GURUGRAM, 122001
HARYANA, INDIA
Tel : 9111591115

Test Report Statu	ıs <u>Final</u>	Results	Biological Reference Interval Units
REFERRING DOCTO	R: SELF		CLIENT PATIENT ID :
DRAWN :		RECEIVED : 11/03/2023 08:51	REPORTED : 14/03/2023 14:36
ACCESSION NO : 0	0282WC000460	AGE: 33 Years SEX : Female	ABHA NO :
PATIENT NAME :	ANSHU SHARMA	۱.	PATIENT ID : ANSHF210789282

Interpretation(s)

The following table describes the probable conditions, in which the analytes are present in urine

Presence of	Conditions	
Proteins	Inflammation or immune illnesses	
Pus (White Blood Cells)	Urinary tract infection, urinary tract or kidney stone, tumors or any kind of kidney impairment	
Glucose	Diabetes or kidney disease	
Ketones	Diabetic ketoacidosis (DKA), starvation or thirst	
Urobilinogen	Liver disease such as hepatitis or cirrhosis	
Blood	Renal or genital disorders/trauma	
Bilirubin	Liver disease	
Erythrocytes	Urological diseases (e.g. kidney and bladder cancer, urolithiasis), urinary tract infection and glomerular diseases	
Leukocytes	Urinary tract infection, glomerulonephritis, interstitial nephritis either acute or chronic, polycystic kidney disease, urolithiasis, contamination by genital secretions	
Epithelial cells	Urolithiasis, bladder carcinoma or hydronephrosis, ureteric stents or	
	bladder catheters for prolonged periods of time	
Granular Casts	Low intratubular pH, high urine osmolality and sodium concentration, interaction with Bence-Jones protein	
Hyaline casts	Physical stress, fever, dehydration, acute congestive heart failure, renal diseases	
Calcium oxalate	Metabolic stone disease, primary or secondary hyperoxaluria, intravenous infusion of large doses of vitamin C, the use of vasodilator naftidrofuryl oxalate or the gastrointestinal lipase inhibitor orlistat, ingestion of ethylene glycol or of star fruit (Averrhoa carambola) or its juice	
Uric acid	arthritis	
Bacteria	Urinary infectionwhen present in significant numbers & with pus cells.	
Trichomonas vaginalis	Vaginitis, cervicitis or salpingitis	

THYROID PANEL, SERUM

T3

116.0

Non-Pregnant Women 80.0 - 200.0 Pregnant Women 1st Trimester:105.0 - 230.0 2nd Trimester:129.0 - 262.0 3rd Trimester:135.0 - 262.0

METHOD : ELECTROCHEMILUMINESCENCE IMMUNO ASSAY





ng/dL







CLIENT'S NAME AND ADDRESS : ACROFEMI HEALTHCARE LTD (MEDIWHEEL) F-703, LADO SARAI, MEHRAULI SOUTH WEST DELHI NEW DELHI 110030 DELHI INDIA 8800465156

SRL Ltd
Shop CG 017, PALM SPRINGS PLAZA
GURUGRAM, 122001
HARYANA, INDIA
Tel : 9111591115

Pregnant Women

1st Trimester: 0.33 - 4.59 2nd Trimester: 0.35 - 4.10 3rd Trimester: 0.21 - 3.15

PATIENT NAME : ANSHU SHARMA	A	PATIENT ID : ANSHF210789282
ACCESSION NO : 0282WC000460	AGE : 33 Years SEX : Female	ABHA NO :
DRAWN :	RECEIVED : 11/03/2023 08:51	REPORTED : 14/03/2023 14:36
REFERRING DOCTOR : SELF		CLIENT PATIENT ID:
Test Report Status Final	Results	Biological Reference Interval Units
T4	8.80	Non-Pregnant Women μg/dL 5.10 - 14.10 Pregnant Women 1st Trimester: 7.33 - 14.80 2nd Trimester: 7.93 - 16.10 3rd Trimester: 6.95 - 15.70
TSH (ULTRASENSITIVE)	2.040	Non Pregnant Women µIU/mL 0.27 - 4.20

METHOD : ELECTROCHEMILUMINESCENCE IMMUNO ASSAY









CLIENT'S NAME AND ADDRESS : ACROFEMI HEALTHCARE LTD (MEDIWHEEL) F-703, LADO SARAI, MEHRAULI SOUTH WEST DELHI NEW DELHI 110030 DELHI INDIA 8800465156

SRL Ltd
Shop CG 017, PALM SPRINGS PLAZA
GURUGRAM, 122001
HARYANA, INDIA
Tel : 9111591115

Test Report Status	Final	Results	Biological Reference Interval Units
REFERRING DOCTOR :	SELF		CLIENT PATIENT ID :
DRAWN :		RECEIVED : 11/03/2023 08:51	REPORTED : 14/03/2023 14:36
ACCESSION NO : 028	2WC000460	AGE : 33 Years SEX : Female	ABHA NO :
PATIENT NAME : AN	ISHU SHARMA	PATIENT ID : ANSHF210789282	

Interpretation(s)

Triiodothyronine T3, Thyroxine T4, and Thyroid Stimulating Hormone TSH are thyroid hormones which affect almost every physiological process in the body, including growth, development, metabolism, body temperature, and heart rate.

Production of T3 and its prohormone thyroxine (T4) is activated by thyroid-stimulating hormone (TSH), which is released from the pituitary gland. Elevated concentrations of T3, and T4 in the blood inhibit the production of TSH.

Excessive secretion of thyroxine in the body is hyperthyroidism, and deficient secretion is called hypothyroidism.

In primary hypothyroidism, TSH levels are significantly elevated, while in secondary and tertiary hyperthyroidism, TSH levels are low. Below mentioned are the guidelines for Pregnancy related reference ranges for Total T4, TSH & Total T3.Measurement of the serum TT3 level is a more sensitive test for the diagnosis of hyperthyroidism, and measurement of TT4 is more useful in the diagnosis of hypothyroidism.Most of the thyroid hormone in blood is bound to transport proteins. Only a very small fraction of the circulating hormone is free and biologically active. It is advisable to detect Free T3, FreeT4 along with TSH, instead of testing for albumin bound Total T3, Total T4.

Sr. No.	ТЅН	Total T4	FT4	Total T3	Possible Conditions
1	High	Low	Low	Low	(1) Primary Hypothyroidism (2) Chronic autoimmune Thyroiditis (3)
					Post Thyroidectomy (4) Post Radio-Iodine treatment
2	High	Normal	Normal	Normal	(1)Subclinical Hypothyroidism (2) Patient with insufficient thyroid
					hormone replacement therapy (3) In cases of Autoimmune/Hashimoto
					thyroiditis (4). Isolated increase in TSH levels can be due to Subclinical
					inflammation, drugs like amphetamines, Iodine containing drug and
					dopamine antagonist e.g. domperidone and other physiological reasons.
3	Normal/Low	Low	Low	Low	(1) Secondary and Tertiary Hypothyroidism
4	Low	High	High	High	(1) Primary Hyperthyroidism (Graves Disease) (2) Multinodular Goitre
					(3)Toxic Nodular Goitre (4) Thyroiditis (5) Over treatment of thyroid
					hormone (6) Drug effect e.g. Glucocorticoids, dopamine, T4
					replacement therapy (7) First trimester of Pregnancy
5	Low	Normal	Normal	Normal	(1) Subclinical Hyperthyroidism
6	High	High	High	High	(1) TSH secreting pituitary adenoma (2) TRH secreting tumor
7	Low	Low	Low	Low	(1) Central Hypothyroidism (2) Euthyroid sick syndrome (3) Recent
					treatment for Hyperthyroidism
8	Normal/Low	Normal	Normal	High	(1) T3 thyrotoxicosis (2) Non-Thyroidal illness
9	Low	High	High	Normal	(1) T4 Ingestion (2) Thyroiditis (3) Interfering Anti TPO antibodies

REF: 1. TIETZ Fundamentals of Clinical chemistry 2.Guidlines of the American Thyroid association during pregnancy and Postpartum, 2011. **NOTE: It is advisable to detect Free T3,FreeT4 along with TSH, instead of testing for albumin bound Total T3, Total T4.**TSH is not affected by variation in thyroid - binding protein. TSH has a diurnal rhythm, with peaks at 2:00 - 4:00 a.m. And troughs at 5:00 - 6:00 p.m. With ultradian variations.

MICROSCOPIC EXAMINATION, STOOL

REMARK

METHOD : MICROSCOPIC EXAMINATION

TEST CANCELLED AS SPECIMEN NOT RECEIVED











CLIENT'S NAME AND ADDRESS : ACROFEMI HEALTHCARE LTD (MEDIWHEEL) F-703, LADO SARAI, MEHRAULI SOUTH WEST DELHI NEW DELHI 110030 DELHI INDIA 8800465156

SRL Ltd
Shop CG 017, PALM SPRINGS PLAZA
GURUGRAM, 122001
HARYANA, INDIA
Tel : 9111591115

Test Report Statu	ıs <u>Final</u>	Results	Biological Reference Interval Units
	R: SELF		CLIENT PATIENT ID:
DRAWN :		RECEIVED : 11/03/2023 08:51	REPORTED : 14/03/2023 14:36
ACCESSION NO : C	0282WC000460	AGE : 33 Years SEX : Female	ABHA NO :
PATIENT NAME :	ANSHU SHARMA	PATIENT ID : ANSHF210789282	

Interpretation(s)

Stool routine analysis is only a screening test for disorders of gastrointentestinal tract like infection, malabsorption, etc. The following table describes the probable conditions, in which the analytes are present in stool.

PRESENCE OF	CONDITION	
Pus cells	Pus in the stool is an indication of infection	
Red Blood cells	Parasitic or bacterial infection or an inflammatory bowel condition such as ulcerative colitis	
Parasites	Infection of the digestive system. Stool examination for ova and parasite detects presence of parasitic infestation of gastrointestinal tract. Various forms of parasite that can be detected include cyst, trophozoite and larvae. One negative result does not rule out the possibility of parasitic infestation. Intermittent shedding of parasites warrants examinations of multiple specimens tested on consecutive days.Stool specimens for parasitic examination should be collected before initiation of antidiarrheal therapy or antiparasitic therapy. This test does not detect presence of opportunistic parasites like Cyclospora, Cryptosporidia and Isospora species. Examination of Ova and Parasite has been carried out by direct and concentration techniques.	
Mucus	Mucus is a protective layer that lubricates, protects& reduces damage due to bacteria or viruses.	
Charcot-Leyden crystal	Parasitic diseases.	
Ova & cyst	Ova & cyst indicate parasitic infestation of intestine.	
Frank blood	Bleeding in the rectum or colon.	
Occult blood	Occult blood indicates upper GI bleeding.	
Macrophages	Macrophages in stool are an indication of infection as they are protective cells.	
Epithelial cells	Epithelial cells that normally line the body surface and internal organs show up in stool when there is inflammation or infection.	
Fat	Increased fat in stool maybe seen in conditions like diarrhoea or malabsorption.	
рН	Normal stool pH is slightly acidic to neutral. Breast-fed babies generally have an acidic stool.	

ADDITIONAL STOOL TESTS :

- 1. <u>Stool Culture</u>:- This test is done to find cause of GI infection, make decision about best treatment for GI infection & to find out if treatment for GI infection worked.
- 2. <u>Fecal Calprotectin</u>: It is a marker of intestinal inflammation. This test is done to differentiate Inflammatory Bowel Disease (IBD) from Irritable Bowel Syndrome (IBS).
- 3. Fecal Occult Blood Test(FOBT): This test is done to screen for colon cancer & to evaluate possible cause of unexplained anaemia.
- 4. <u>Clostridium Difficile Toxin Assay</u>: This test is strongly recommended in healthcare associated bloody or waterydiarrhoea, due to overuse of broad spectrum antibiotics which alter the normal GI flora.
- Biofire (Film Array) GI PANEL: In patients of Diarrhoea, Dysentry, Rice watery Stool, FDA approved, Biofire Film Array Test,(Real Time Multiplex PCR) is strongly recommended as it identifies organisms, bacteria, fungi, virus, parasite and other opportunistic pathogens, Vibrio cholera infections only in 3 hours. Sensitivity 96% & Specificity 99%.
- 6. <u>Rota Virus Immunoassay</u>: This test is recommended in severe gastroenteritis in infants & children associated with watery diarrhoea, vomitting& abdominal cramps. Adults are also affected. It is highly contagious in nature.











CLIENT'S NAME AND ADDRESS : ACROFEMI HEALTHCARE LTD (MEDIWHEEL) F-703, LADO SARAI, MEHRAULI SOUTH WEST DELHI NEW DELHI 110030 DELHI INDIA 8800465156

SRL Ltd
Shop CG 017, PALM SPRINGS PLAZA
GURUGRAM, 122001
HARYANA, INDIA
Tel : 9111591115

Test Report Status	inal	Re	esults	Biological F	Reference I	nterval Units
REFERRING DOCTOR : SE	ELF			CLIEN	T PATIENT ID:	
DRAWN :	REC	EIVED : 11/03	/2023 08:51	REPORTED :	14/03/202	3 14:36
ACCESSION NO : 0282W	/C000460 AGE :	33 Years	SEX : Female	ABHA NO :		
PATIENT NAME : ANSH	IU SHARMA			PA	TIENT ID:	ANSHF210789282

ABO GROUP & RH TYPE, EDTA WHOLE BLOOD		
ABO GROUP	0	
METHOD : HEMAGGLUTINATION REACTION ON SOLID PHASE		
RH TYPE	RH+	
METHOD : HEMAGGLUTINATION REACTION ON SOLID PHASE		
XRAY-CHEST		
»»	BOTH THE LUNG FIELDS ARE CLEAR	
»»	BOTH THE COSTOPHRENIC AND CARDIOPHRENIC ANGLES A	ARE CLEAR
»»	BOTH THE HILA ARE NORMAL	
»»	CARDIAC AND AORTIC SHADOWS APPEAR NORMAL	
»»	BOTH THE DOMES OF THE DIAPHRAGM ARE NORMAL	
»»	VISUALIZED BONY THORAX IS NORMAL	
IMPRESSION	NO ABNORMALITY DETECTED	
TMT OR ECHO		
TMT OR ECHO	ECHO REPORT	
ECG	 Normal sized cardiac chambers and normal valv No RWMA Trivlal TR Normal LV systolic function LVEF ~ 60 % Normal LV diastolic function, E>A No Clot/Vegetation/Pericardial Effusion IVS/IAS intact, no flow seen across. 	res
ECG	WITHIN NORMAL LIMITS	
MEDICAL HISTORY		
RELEVANT PRESENT HISTORY	NOT SIGNIFICANT	
RELEVANT PAST HISTORY	H/O LSCS	
RELEVANT PERSONAL HISTORY	MARRIED , ONE CHILD	
MENSTRUAL HISTORY (FOR FEMALES)	NORMAL	
LMP (FOR FEMALES)	7/03/23	
RELEVANT FAMILY HISTORY	DIABETES - MOTHER	
OCCUPATIONAL HISTORY	SERVICE	
HISTORY OF MEDICATIONS	NOT SIGNIFICANT	
ANTHROPOMETRIC DATA & BMI		
HEIGHT IN METERS	1.57	mts











CLIENT'S NAME AND ADDRESS : ACROFEMI HEALTHCARE LTD (MEDIWHEEL) F-703, LADO SARAI, MEHRAULI SOUTH WEST DELHI NEW DELHI 110030 DELHI INDIA 8800465156

SRL Ltd
Shop CG 017, PALM SPRINGS PLAZA
GURUGRAM, 122001
HARYANA, INDIA
Tel : 9111591115

PATIENT NAME : ANSHU SHARMA		PATIENT ID : ANSHF21078928
ACCESSION NO : 0282WC000460 AGE : 33 Y	ears SEX : Female	ABHA NO :
DRAWN : RECEIVED :	11/03/2023 08:51	REPORTED : 14/03/2023 14:36
REFERRING DOCTOR : SELF		CLIENT PATIENT ID:
Test Report Status <u>Final</u>	Results	Biological Reference Interval Units
WEIGHT IN KGS.	68	Kgs
BMI	28	BMI & Weight Status as follows: kg/sqmts Below 18.5: Underweight 18.5 - 24.9: Normal 25.0 - 29.9: Overweight 30.0 and Above: Obese
GENERAL EXAMINATION		
MENTAL / EMOTIONAL STATE	NORMAL	
PHYSICAL ATTITUDE	NORMAL	
GENERAL APPEARANCE / NUTRITIONAL STATUS	OVERWEIGHT	
BUILT / SKELETAL FRAMEWORK	AVERAGE	
FACIAL APPEARANCE	NORMAL	
SKIN	NORMAL	
UPPER LIMB	NORMAL	
LOWER LIMB	NORMAL	
NECK	NORMAL	
NECK LYMPHATICS / SALIVARY GLANDS	NOT ENLARGED OR TEN	IDER
THYROID GLAND	NOT ENLARGED	
CAROTID PULSATION	NORMAL	
TEMPERATURE	NORMAL	
PULSE	82/ MINUTE, REGULAR,	ALL PERIPHERAL PULSES FELT.
RESPIRATORY RATE	NORMAL	
CARDIOVASCULAR SYSTEM		
BP PERICARDIUM	110/80 MMHG (SUPINE) NORMAL	mm/Hg
APEX BEAT	NORMAL	
HEART SOUNDS	NORMAL	
MURMURS	ABSENT	
RESPIRATORY SYSTEM		
SIZE AND SHAPE OF CHEST	NORMAL	
MOVEMENTS OF CHEST	SYMMETRICAL	
BREATH SOUNDS INTENSITY	NORMAL	
BREATH SOUNDS QUALITY	VESICULAR (NORMAL)	
ADDED SOUNDS	ABSENT	
	ADOLINI	

Scan to View Details

PER ABDOMEN









CLIENT'S NAME AND ADDRESS : ACROFEMI HEALTHCARE LTD (MEDIWHEEL) F-703, LADO SARAI, MEHRAULI SOUTH WEST DELHI NEW DELHI 110030 DELHI INDIA 8800465156

SRL Ltd
Shop CG 017, PALM SPRINGS PLAZA
GURUGRAM, 122001
HARYANA, INDIA
Tel : 9111591115

PATIENT NAME : ANSHU SHARMA PATIENT ID : ANSHF21078			
ACCESSION NO : 0282WC000460	AGE : 33 Years SEX : Female	ABHA NO :	
DRAWN :	RECEIVED : 11/03/2023 08:51	REPORTED : 14/03/2023 14:36	
REFERRING DOCTOR : SELF		CLIENT PATIENT ID:	

Test Report Status <u>Final</u>	Results	Biological Reference Interval	Units
APPEARANCE	NORMAL		
VENOUS PROMINENCE	ABSENT		
LIVER	NOT PALPABLE		
SPLEEN	NOT PALPABLE		
CENTRAL NERVOUS SYSTEM			
HIGHER FUNCTIONS	NORMAL		
CRANIAL NERVES	NORMAL		
CEREBELLAR FUNCTIONS	NORMAL		
SENSORY SYSTEM	NORMAL		
MOTOR SYSTEM	NORMAL		
REFLEXES	NORMAL		
MUSCULOSKELETAL SYSTEM			
SPINE	NORMAL		
JOINTS	NORMAL		
BASIC EYE EXAMINATION			
DISTANT VISION RIGHT EYE WITHOUT GLASSES	6/6		
DISTANT VISION LEFT EYE WITHOUT GLASSES	6/6		
NEAR VISION RIGHT EYE WITHOUT GLASSES	N/6		
NEAR VISION LEFT EYE WITHOUT GLASSES	N/6		
COLOUR VISION	17/17		
SUMMARY			
REMARKS / RECOMMENDATIONS	ADVISED LIFESTYLE CHANGES PLENTY OF ORAL FLUIDS, FOLLOW UP WITH PHYSIC	TAN	

WITH PHYSICIAN OLLOW UP REVIEW WITH PAP REPORT.

Interpretation(s)

BLOOD COUNTS, EDTA WHOLE BLOOD-The cell morphology is well preserved for 24hrs. However after 24-48 hrs a progressive increase in MCV and HCT is observed leading to a decrease in MCHC. A direct smear is recommended for an accurate differential count and for examination of RBC morphology. RBC AND PLATELET INDICES-Mentzer index (MCV/RBC) is an automated cell-counter based calculated screen tool to differentiate cases of Iron deficiency anaemia(>13) from Beta thalassaemia trait

(<13) in patients with microcytic anaemia. This needs to be interpreted in line with clinical correlation and suspicion. Estimation of HbA2 remains the gold standard for diagnosing a case of beta thalassaemia trait. WBC DIFFERENTIAL COUNT-The optimal threshold of 3.3 for NLR showed a prognostic possibility of clinical symptoms to change from mild to severe in COVID positive

patients. When age = 49.5 years old and NLR = 3.3, 46.1% COVID-19 patients with mild disease might become severe. By contrast, when age < 49.5 years old and NLR < 3.3, COVID-19 patients tend to show mild disease. (Reference to - The diagnostic and predictive role of NLR, d-NLR and PLR in COVID-19 patients A.-P. Yang, et al. International Immunopharmacology 84 (2020) 106504

This ratio element is a calculated parameter and out of NABL scope.











CLIENT'S NAME AND ADDRESS : ACROFEMI HEALTHCARE LTD (MEDIWHEEL) F-703, LADO SARAI, MEHRAULI SOUTH WEST DELHI NEW DELHI 110030 DELHI INDIA 8800465156

SRL Ltd
Shop CG 017, PALM SPRINGS PLAZA
GURUGRAM, 122001
HARYANA, INDIA
Tel : 9111591115

Test Report Statu	ıs <u>Final</u>	Results	Biological Reference Interval Units
REFERRING DOCTO	R: SELF		CLIENT PATIENT ID :
DRAWN :		RECEIVED : 11/03/2023 08:51	REPORTED : 14/03/2023 14:36
ACCESSION NO : C	0282WC000460	AGE : 33 Years SEX : Female	ABHA NO :
PATIENT NAME :	ANSHU SHARMA		PATIENT ID : ANSHF210789282

ERYTHROCYTE SEDIMENTATION RATE (ESR), WHOLE BLOOD-TEST DESCRIPTION :-

Erythrocyte sedimentation rate (ESR) is a test that indirectly measures the degree of inflammation present in the body. The test actually measures the rate of fall (sedimentation) of erythrocytes in a sample of blood that has been placed into a tall, thin, vertical tube. Results are reported as the millimetres of clear fluid (plasma) that are present at the top portion of the tube after one hour. Nowadays fully automated instruments are available to measure ESR.

ESR is not diagnostic it is a non-specific test that may be elevated in a number of different conditions. It provides general information about the presence of an inflammatory condition.CRP is superior to ESR because it is more sensitive and reflects a more rapid change. TEST INTERPRETATION

Increase in: Infections, Vasculities, Inflammatory arthritis, Renal disease, Anemia, Malignancies and plasma cell dyscrasias, Acute allergy Tissue injury, Pregnancy,

Estrogen medication, Aging. Finding a very accelerated ESR(>100 mm/hour) in patients with ill-defined symptoms directs the physician to search for a systemic disease (Paraproteinemias,

In pregnancy BRI in first trimester is 0-48 mm/hr(62 if anemic) and in second trimester (0-70 mm /hr(95 if anemic). ESR returns to normal 4th week post partum. **Decreased** in: Polycythermia vera, Sickle cell anemia

LIMITATIONS

False elevated ESR : Increased fibrinogen, Drugs(Vitamin A, Dextran etc), Hypercholesterolemia

False Decreased : Poikilocytosis, (SickleCells, spherocytes), Microcytosis, Low fibrinogen, Very high WBC counts, Drugs (Quinine,

salicylates)

REFERENCE :

1. Nathan and Oski's Haematology of Infancy and Childhood, 5th edition 2. Paediatric reference intervals. AACC Press, 7th edition. Edited by S. Soldin 3. The reference for the adult reference range is "Practical Haematology by Dacie and Lewis,10th edition.

GLUCOSE FASTING, FLUORIDE PLASMA-TEST DESCRIPTION

Normally, the glucose concentration in extracellular fluid is closely regulated so that a source of energy is readily available to tissues and sothat no glucose is excreted in the urine.

Increased in:Diabetes mellitus, Cushing's syndrome (10 – 15%), chronic pancreatitis (30%). Drugs:corticosteroids,phenytoin, estrogen, thiazides. Decreased in :Pancreatic islet cell disease with increased insulin,insulinoma,adrenocortical insufficiency,hypopituitarism,diffuse liver disease, malignancy(adrenocortical,stomach,fibrosarcoma),infant of a diabetic mother,enzyme deficiency diseases(e.g.galactosemia),Drugs-insulin,ethanol,propranolol

sulfonylureas,tolbutamide, and other oral hypoglycemic agents. NOTE: While random serum glucose levels correlate with home glucose monitoring results (weekly mean capillary glucose values), there is wide fluctuation within individuals. Thus, glycosylated hemoglobin (HbA1c) levels are favored to monitor glycemic control.

High fasting glucose level in comparison to post prandial glucose level may be seen due to effect of Oral Hypoglycaemics & Insulin treatment, Renal Glyosuria, Glycaemic index & response to food consumed, Alimentary Hypoglycemia, Increased insulin response & sensitivity etc. GLYCOSYLATED HEMOGLOBIN(HBA1C), EDTA WHOLE BLOOD-Used For:

1. Evaluating the long-term control of blood glucose concentrations in diabetic patients.

Diagnosing diabetes.
 Identifying patients at increased risk for diabetes (prediabetes).

The ADA recommends measurement of HbAIc (typically 3-4 times per year for type 1 and poorly controlled type 2 diabetic patients, and 2 times per year for well-controlled type 2 diabetic patients) to determine whether a patients metabolic control has remained continuously within the target range.

- eAG (Estimated average glucose) converts percentage HbA1c to md/dl, to compare blood glucose levels.
 eAG gives an evaluation of blood glucose levels for the last couple of months.
 eAG is calculated as eAG (mg/dl) = 28.7 * HbA1c 46.7

HbA1c Estimation can get affected due to :

1. Shortened Erythrocyte survival : Any condition that shortens erythrocyte survival or decreases mean erythrocyte age (e.g. recovery from acute blood loss, hemolytic anemia) will falsely lower HbA1c test results. Fructosamine is recommended in these patients which indicates diabetes control over 15 days. 2.Vitamin C & E are reported to falsely lower test results.(possibly by inhibiting glycation of hemoglobin.

3. Iron deficiency anemia is reported to increase test results. Hypertriglyceridemia, uremia, hyperbilirubinemia, chronic alcoholism, chronic ingestion of salicylates & opiates addiction are reported to interfere with some assay methods, falsely increasing results.

4. Interference of hemoglobinopathies in HbA1c estimation is seen in

a) Homozygous hemoglobinopathy. Fructosamine is recommended for testing of HbA1c.

b) Heterozygous state detected (D10 is corrected for HbS & HbC trait.) c) HbF > 25% on alternate paltform (Boronate affinity chromatography) is recommended for testing of HbA1c.Abnormal Hemoglobin electrophoresis (HPLC method) is

GLUCOSE, POST-PRANDIAL, PLASMA-High fasting glucose level in comparison to post prandial glucose level may be seen due to effect of Oral Hypoglycaemics & Insulin treatment, Renal Glyosuria, Glycaemic index & response to food consumed, Alimentary Hypoglycemia, Increased insulin response & sensitivity etc.Additional test HbA1c LIVER FUNCTION PROFILE, SERUM-

Bilirubin is a yellowish pigment found in bile and is a breakdown product of normal heme catabolism. Bilirubin is excreted in bile and urine, and elevated levels may give vellow discoloration in jaundice. Elevated levels results from increased bilirubin production (eg, hemolysis and ineffective erythropoiesis), decreased bilirubin excretion (eg, obstruction and hepatitis), and abnormal bilirubin metabolism (eg, hereditary and neonatal jaundice). Conjugated (direct) bilirubin is elevated more than unconjugated




Scan to View Details





Patient Ref. No. 775000002565718



8800465156

CLIENT'S NAME AND ADDRESS : ACROFEMI HEALTHCARE LTD (MEDIWHEEL) F-703, LADO SARAI, MEHRAULI SOUTH WEST DELHI NEW DELHI 110030 DELHI INDIA

SRL	1
Diagnostics	5

SRL Ltd Shop CG 017, PALM SPRINGS PLAZA GURUGRAM, 122001 HARYANA, INDIA Tel: 9111591115

Test Report Stat	us <u>Final</u>	Results	Biological Reference Interval Units
REFERRING DOCTO	DR: SELF		CLIENT PATIENT ID :
DRAWN :		RECEIVED : 11/03/2023 08:51	REPORTED : 14/03/2023 14:36
ACCESSION NO :	0282WC000460	AGE : 33 Years SEX : Female	ABHA NO :
PATIENT NAME	: ANSHU SHARMA	L Contraction of the second	PATIENT ID : ANSHF210789282

(indirect) bilirubin in Viral hepatitis, Drug reactions, Alcoholic liver disease Conjugated (direct) bilirubin is also elevated more than unconjugated (indirect) bilirubin when there is some kind of blockage of the bile ducts like in Gallstones getting into the bile ducts, tumors &Scarring of the bile ducts. Increased unconjugated (indirect) bilirubin may be a result of Hemolytic or pernicious anemia, Transfusion reaction & a common metabolic condition termed Gilbert syndrome, due to low levels of the enzyme that attaches sugar molecules to bilirubin. AST is an enzyme found in various parts of the body. AST is found in the liver, heart, skeletal muscle, kidneys, brain, and red blood cells, and it is commonly measured

consistence of the second seco is found mainly in the liver, but also in smaller amounts in the kidneys, heart, muscles, and pancreas. It is commonly measured as a part of a diagnostic evaluation of hepatocellular injury, to determine liver health.AST levels increase during acute hepatitis, sometimes due to a viral infection, ischemia to the liver, chronic hepatitis, obstruction of bile ducts, cirrhosis.

ALP is a protein found in almost all body tissues. Tissues with higher amounts of ALP include the liver, bile ducts and bone. Elevated ALP levels are seen in Biliary obstruction, osteoblastic bone tumors, osteomalacia, hepatitis, Hyperparathyroidism, Leukemia, Lymphoma, Pagets disease, Rickets, Sarcoidosis etc. Lower-than-normal ALP levels seen in Hypophosphatasia, Malnutrition, Protein deficiency, Wilsons disease.

GGT is an enzyme found in cell membranes of many tissues mainly in the liver,kidney and pancreas. It is also found in other tissues including intestine, spleen, heart, brain and seminal vesicles. The highest concentration is in the kidney, but the liver is considered the source of normal enzyme activity. Serum GGT has been widely used as an index of liver dysfunction. Elevated serum GGT activity can be found in diseases of the liver, biliary system and pancreas. Conditions that increase serum GGT are obstructive

liver disease, high alcohol consumption and use of enzyme-inducing drugs etc. **Total Protein** also known as total protein, is a biochemical test for measuring the total amount of protein in serum.Protein in the plasma is made up of albumin and globulin.Higher-than-normal levels may be due to:Chronic inflammation or infection, including HIV and hepatitis B or C, Multiple myeloma, Waldenstroms disease.Lower-than-normal levels may be due to: Agammaglobulinemia, Bleeding (hemorrhage), Burns, Glomerulonephritis, Liver disease, Malabsorption, Malnutrition, Nephrotic syndrome, Protein-losing enteropathy etc.

(hypoalbuminemia) can be caused by:Liver disease like cirrhosis of the liver, nephrotic syndrome, protein-losing enteropathy,Burns,hemodilution,increased vascular

permeability or decreased lymphatic clearance, malnutrition and wasting etc BLOOD UREA NITROGEN (BUN), SERUM-**Causes of Increased** levels include Pre renal (High protein diet, Increased protein catabolism, GI haemorrhage, Cortisol, Dehydration, CHF Renal), Renal Failure, Post Renal (Malignancy, Nephrolithiasis, Prostatism) Causes of decreased level include Liver disease, SIADH.

CREATININE, SERUM-Higher than normal level may be due to:

• Blockage in the unitary track, Kidney problems, such as kidney damage or failure, infection, or reduced blood flow, Loss of body fluid (dehydration), Muscle problems, such as breakdown of muscle fibers, Problems during pregnancy, such as seizures (eclampsia)), or high blood pressure caused by pregnancy (preeclampsia) Lower than normal level may be due to:

Myasthenia Gravis, Muscuophy

URIC ACID, SERUM-Causes of Increased levels:-Dietary(High Protein Intake, Prolonged Fasting, Rapid weight loss), Gout, Lesch nyhan syndrome, Type 2 DM, Metabolic syndrome Causes of decreased levels-Low Zinc intake, OCP, Multiple Sclerosis

TOTAL PROTEIN, SERUM-is a biochemical test for measuring the total amount of protein in serum. Protein in the plasma is made up of albumin and globulin.

Higher-than-normal levels may be due to: Chronic inflammation or infection, including HIV and hepatitis B or C, Multiple myeloma, Waldenstroms disease. Lower-than-normal levels may be due to: Agammaglobulinemia, Bleeding (hemorrhage), Burns, Glomerulonephritis, Liver disease, Malabsorption, Malnutrition, Nephrotic syndrome, Protein-losing enteropathy etc.

ALBUMIN, SERUM-Human serum albumin is the most abundant protein in human blood plasma. It is produced in the liver. Albumin constitutes about half of the blood serum protein. Low blood albumin levels (hypoalbuminemia) can be caused by: Liver disease like cirrhosis of the liver, nephrotic syndrome, protein-losing enteropathy, Burns, hemodilution, increased vascular permeability or decreased lymphatic clearance,malnutrition and wasting etc. ABO GROUP & RH TYPE, EDTA WHOLE BLOOD-Blood group is identified by antigens and antibodies present in the blood. Antigens are protein molecules found on the surface

of red blood cells. Antibodies are found in plasma. To determine blood group, red cells are mixed with different antibody solutions to give A,B,O or AB.

Disclaimer: "Please note, as the results of previous ABO and Rh group (Blood Group) for pregnant women are not available, please check with the patient records for availability of the same.


The test is performed by both forward as well as reverse grouping methods. MEDICAL

THIS REPORT CARRIES THE SIGNATURE OF OUR LABORATORY DIRECTOR. THIS IS AN INVIOLABLE FEATURE OF OUR LAB MANAGEMENT SOFTWARE. HOWEVER, ALL EXAMINATIONS AND INVESTIGATIONS HAVE BEEN CONDUCTED BY OUR PANEL OF DOCTORS.











CLIENT'S NAME AND ADDRESS : ACROFEMI HEALTHCARE LTD (MEDIWHEEL) F-703, LADO SARAI, MEHRAULI SOUTH WEST DELHI NEW DELHI 110030 DELHI INDIA 8800465156

PATIENT NAME : ANSHU SHARMA

SRL Ltd
Shop CG 017, PALM SPRINGS PLAZA
GURUGRAM, 122001
HARYANA, INDIA
Tel : 9111591115

Test Report Sta	tus <u>Final</u>	Results	Units
REFERRING DOCT	OR: SELF		CLIENT PATIENT ID :
DRAWN :		RECEIVED : 11/03/2023 08:51	REPORTED : 14/03/2023 14:36
ACCESSION NO :	0282WC000460	AGE : 33 Years SEX : Female	ABHA NO :
PATIENT NAME	: ANSHU SHARM	A.	PATIENT ID : ANSHF210789282

MEDI WHEEL FULL BODY HEALTH CHECKUP BELOW 40FEMALE

<u>Final</u>

ULTRASOUND ABDOMEN **ULTRASOUND ABDOMEN** U.S.G Scan S/o Small right renal calculus. No other significant abnormality.

> **End Of Report** Please visit www.srlworld.com for related Test Information for this accession

Dr. Deblina Naithani **Consultant Physician**

CONDITIONS OF LABORATORY TESTING & REPORTING			
1. It is presumed that the test sample belongs to the patient	5. SRL confirms that all tests have been performed or		
named or identified in the test requisition form.	assayed with highest quality standards, clinical safety &		
All tests are performed and reported as per the	technical integrity.		
turnaround time stated in the SRL Directory of Services.	6. Laboratory results should not be interpreted in isolation;		
3. Result delays could occur due to unforeseen	it must be correlated with clinical information and be		
circumstances such as non-availability of kits / equipment	interpreted by registered medical practitioners only to		
breakdown / natural calamities / technical downtime or any	determine final diagnosis.		
other unforeseen event.	7. Test results may vary based on time of collection,		
A requested test might not be performed if:	physiological condition of the patient, current medication or		
i. Specimen received is insufficient or inappropriate	nutritional and dietary changes. Please consult your doctor		

- i. Speci ii. Specimen quality is unsatisfactory
- iii. Incorrect specimen type
- iv. Discrepancy between identification on specimen container label and test requisition form

or call us for any clarification.

- 8. Test results cannot be used for Medico legal purposes.
- 9. In case of queries please call customer care
- (91115 91115) within 48 hours of the report.

SRL Limited

Fortis Hospital, Sector 62, Phase VIII, Mohali 160062



